Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Hypothesis:
AR-67 (formerly DB-67) represents a rationally engineered drug that possesses improved
stability, toxicity, and efficacy compared to current Food and Drug Administration
(FDA)-approved camptothecins, based on the extensive research of prior studies. Therefore,
the investigators hypothesize that AR-67 (formerly DB-67) will be well-tolerated and
efficacious in phase I clinical trials. This initial phase I trial will establish the maximum
tolerated dose in humans, establish the toxicity profile, and define the appropriate dose of
AR-67 (formerly DB-67) for future phase II and III clinical trials.
Phase:
Phase 1
Details
Lead Sponsor:
Arno Therapeutics
Collaborators:
Arch Medical Services Inc., DBA The Center for Cancer Care and Research University of Kentucky